Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFLAMMACOV: Anakinra, Tocilizumab +/- Ruxolitinib in Severe COVID-19
NCT04424056Phase 3Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Small Molecules, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of anakinra, tocilizumab, ruxolitinib in coronavirus disease 2019 (COVID-19), sponsored by Assistance Publique-Hôpitaux de Marseille. Status: unknown.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04424056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424056.